Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Rectal Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Endometrial Neoplasms 1Anus Neoplasms 1

Interventions

Cyclophosphamide 7pembrolizumab 6fludarabine 6aldesleukin 4fludarabine phosphate 2entinostat 2Trastuzumab 2Radiotherapy 2Psychiatric Rehabilitation 2Nivolumab 2Interleukin-2 2Interleukin-12 Subunit p35 2Early Intervention, Educational 2Adoptive Transfer 2trastuzumab deruxtecan 1tislelizumab 1tipifarnib 1spartalizumab 1rocakinogene sifuplasmid 1oncogene protein E7, Human papillomavirus type 16 1enzalutamide 1durvalumab 1cemiplimab 1bintrafusp alfa protein, human 1atezolizumab 1alovudine 1abiraterone 1Vorinostat 1Vaccines, Synthetic 1VGX-3100 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anus Neoplasms × alovudine × Genitourinary × Clear all
NCT01717391 2019-03-26

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

University of Iowa

Phase 2 Completed
36 enrolled 5 charts
GastrointestinalGenitourinaryGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡